Eliem Therapeutics, Inc Common Stock

Eliem Therapeutics, Inc. is changing its name to Climb Bio, Inc. and will begin trading on Nasdaq under the new ticker symbol 'CLYM' on October 3, 2024. The company is refocusing its mission on developing treatments for immune-mediated diseases, with its lead product candidate budoprutug, an anti-CD19 monoclonal antibody, showing promising results in a Phase 1b trial for membranous nephropathy.

Related tickers: ELYM.

Eliem Therapeutics, a biopharmaceutical company focused on autoimmune-driven inflammatory diseases, announced that members of its management team will participate in the Stifel 2024 Virtual Immunology and Inflammation Summit.

Related tickers: ELYM.